arcadia biosciences inc - RKDA

RKDA

Close Chg Chg %
1.33 0.01 0.75%

Pre-Market

1.34

+0.01 (0.75%)

Volume: 7.50K

Last Updated:

Apr 9, 2026, 4:00 PM EDT

Company Overview: arcadia biosciences inc - RKDA

RKDA Key Data

Open

$1.37

Day Range

1.33 - 1.38

52 Week Range

1.30 - 6.71

Market Cap

$2.74M

Shares Outstanding

2.06M

Public Float

2.04M

Beta

0.72

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.71

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

44.61K

 

RKDA Performance

1 Week
 
-0.89%
 
1 Month
 
-25.56%
 
3 Months
 
-51.27%
 
1 Year
 
-58.13%
 
5 Years
 
-98.73%
 

RKDA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About arcadia biosciences inc - RKDA

Arcadia Biosciences, Inc. is an agricultural biotechnology company, which engages in the development of agricultural products. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. Its products include Zola coconut water and agronomic wheat traits. It operates through the following geographical segments: United States, Argentina, India, and Canada. The company was founded by John G. Sperling in 2002 and is headquartered in Dallas, TX.

RKDA At a Glance

Arcadia Biosciences, Inc.
5950 Sherry Lane
Dallas, Texas 75225
Phone 1-214-974-8921 Revenue 4.86M
Industry Chemicals: Agricultural Net Income -2,339,000.00
Sector Process Industries Employees 8
Fiscal Year-end 12 / 2026
View SEC Filings

RKDA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.558
Price to Book Ratio 0.657
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.188
Enterprise Value to Sales -0.382
Total Debt to Enterprise Value N/A

RKDA Efficiency

Revenue/Employee 607,250.00
Income Per Employee -292,375.00
Receivables Turnover 11.431
Total Asset Turnover 0.484

RKDA Liquidity

Current Ratio 3.087
Quick Ratio 2.498
Cash Ratio 2.216

RKDA Profitability

Gross Margin 36.229
Operating Margin -205.743
Pretax Margin -47.983
Net Margin -48.147
Return on Assets -23.317
Return on Equity -45.141
Return on Total Capital -56.498
Return on Invested Capital -45.141

RKDA Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Arcadia Biosciences Inc - RKDA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
9.96M 5.33M 5.04M 4.86M
Sales Growth
+46.84% -46.46% -5.35% -3.71%
Cost of Goods Sold (COGS) incl D&A
9.80M 3.30M 2.96M 3.10M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.36M 984.00K 765.00K 154.00K
Depreciation
1.32M 984.00K 765.00K 154.00K
Amortization of Intangibles
- - - 40.00K
-
COGS Growth
+12.56% -66.33% -10.21% +4.56%
Gross Income
154.00K 2.03M 2.08M 1.76M
Gross Income Growth
+107.99% +1,218.18% +2.56% -15.47%
Gross Profit Margin
+1.55% +38.09% +41.27% +36.23%
2022 2023 2024 2025 5-year trend
SG&A Expense
19.56M 15.89M 7.69M 11.76M
Research & Development
1.51M 1.39M 53.00K 9.00K
Other SG&A
18.05M 14.51M 7.64M 11.75M
SGA Growth
-24.71% -18.72% -51.59% +52.78%
Other Operating Expense
- - - -
-
Unusual Expense
(2.35M) (355.00K) 3.51M (4.38M)
EBIT after Unusual Expense
(17.06M) (13.51M) (9.12M) (5.61M)
Non Operating Income/Expense
1.46M 353.00K 4.81M 3.28M
Non-Operating Interest Income
289.00K 695.00K 782.00K 221.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(15.60M) (13.16M) (4.31M) (2.33M)
Pretax Income Growth
+3.31% +15.65% +67.25% +45.90%
Pretax Margin
-156.67% -246.85% -85.41% -47.98%
Income Tax
14.00K 8.00K 8.00K 8.00K
Income Tax - Current - Domestic
13.00K 7.00K 8.00K 8.00K
Income Tax - Current - Foreign
- - 1.00K 1.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(15.61M) (13.16M) (4.32M) (2.34M)
Minority Interest Expense
- - (236.00K) (5.00K)
-
Net Income
(15.38M) (13.16M) (4.32M) (2.34M)
Net Income Growth
-4.88% +14.41% +67.20% +45.82%
Net Margin Growth
-154.44% -246.90% -85.57% -48.15%
Extraordinaries & Discontinued Operations
- - (821.00K) (2.72M)
-
Discontinued Operations
- - (821.00K) (2.72M)
-
Net Income After Extraordinaries
(15.38M) (13.98M) (7.04M) (2.34M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(15.38M) (13.98M) (7.04M) (2.34M)
EPS (Basic)
-25.6528 -11.3029 -5.1625 -1.7097
EPS (Basic) Growth
+6.91% +55.94% +54.33% +66.88%
Basic Shares Outstanding
599.39K 1.24M 1.36M 1.37M
EPS (Diluted)
-25.6528 -11.3029 -5.1625 -1.7097
EPS (Diluted) Growth
+6.91% +55.94% +54.33% +66.88%
Diluted Shares Outstanding
599.39K 1.24M 1.36M 1.37M
EBITDA
(18.04M) (12.88M) (4.85M) (9.84M)
EBITDA Growth
+32.84% +28.60% +62.37% -103.03%
EBITDA Margin
-181.20% -241.67% -96.08% -202.57%

Snapshot

Average Recommendation BUY Average Target Price 12.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.97 Median PE on CY Estimate N/A
Year Ago Earnings -1.71 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Arcadia Biosciences Inc in the News